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 Nevertheless, both sphingolipid mime-
tics and small-molecule inhibitors of 
sphingolipid-metabolizing enzymes have 
already been developed, lending credence 
to the view that these are  ‘ druggable ’ 
pathways. Th ese include FTY720 (fi ngoli-
mod) and Genz-112638 (eliglustat). 
FTY720 is a structural homolog of myri-
ocin, a fungal product and sphingosine 
analog. FTY720 is phosphorylated  in vivo 
by sphingosine kinase 2 and subsequently 
binds to sphingosine-1-phosphate recep-
tors or inhibits intracellular targets such 
as cPLA2 and ceramide synthase. The 
immunosuppressive eff ects of FTY720 are 
believed to be secondary to the prevention 
of the egress of lymphocytes from lymph 
nodes. 6 FTY720 has been reported to 
reduce the frequency of relapses in multi-
ple sclerosis. A regulatory fi ling seeking 
approval for the treatment of multiple 
sclerosis was recently announced. The 
development of FTY720 was halted when 
the compound was found to be no more 
eff ective than conventional therapy in the 
prevention of organ rejection. Genz-
112638 is a highly selective inhibitor of 
glucosylceramide synthase. This com-
pound blocks the glycosylation of cera-
mide to form glucosylceramide, the base 
cerebroside for more than 80 % of mam-
malian glycosphingolipids. Recent phase 
2 trials of the use of Genz-112638 for the 
treatment of type I Gaucher ’ s disease have 
reported that this oral compound is com-
parable to enzyme replacement therapy in 
the reduction of spleen size and the 
improvement of anemia and thrombo-
cytopenia. 7 Phase 3 trials are currently in 
progress. Proof-of-concept studies have 
also been conducted with this class of 
compounds in mouse models of Fabry ’ s 
disease, suggesting that inhibition of gly-
cosphingolipids with Genz-112638, 
including globotriaosylceramide, will also 
provide an alternative treatment strategy 
for this renal disease. 
 Th us sphingolipid biology off ers a new 
window that may not only shed light on 
the old problem of dissociating the anti-
infl ammatory eff ects of GC from its secon-
dary metabolic actions, but may off er new 
strategies for the development of novel 
therapeutics. Although it remains to be 
proven whether specific sphingolipids 
mediate infl ammatory and autoimmune 
diseases of the kidney, these metabolites 
have already been demonstrated to medi-
ate inflammatory and proliferative 
responses in a variety of other organs and 
pathological settings. For clinicians and 
investigators focused on renal infl amma-
tory disease, these pathways pose new rid-
dles to be solved. 
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 Hyperphosphatemia has been linked 
with increased mortality and cardio-
vascular disease in chronic kidney 
disease (CKD). Although control of 
serum phosphorus levels can be obtained 
with prolonged nocturnal dialysis by 
itself, 1 the vast majority of patients receiv-
ing currently recommended dialysis 
regimens require the use of phosphate-
binding agents. 
 Th e ideal phosphate binder has yet to be 
identifi ed, and today there are multiple 
options for prescribing such agents. Nearly 
40 years ago, aluminum-based binders 
were introduced, and although eff ective, 
chronic administration led to signifi cant 
tissue accumulation and to the develop-
ment of encephalopathy, osteomalacia, 
myopathy, and microcytic anemia. Such 
compounds were replaced by calcium-
based binders, which are both eff ective 
and inexpensive. However, the success of 
calcium-based binders has been tempered 
by evidence that their use leads to higher 
serum calcium levels, more frequent epi-
sodes of hypercalcemia, adynamic bone 
disease, diminished bone buff er capacity, 
and vascular calcifi cations. 2 – 4 
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 Th e concern that calcium-based binders 
place patients in positive calcium balance 
led to the development of sevelamer 
hydrochloride, a calcium-free, metal-free 
cation polymer. Sevelamer hydrochloride, 
approved by the US Food and Drug 
Administration (FDA) in 2000, was found 
to be as eff ective as calcium-based binders, 
but its administration leads to lower 
serum calcium levels, fewer hypercalcemic 
episodes, attenuation of vascular calcifi ca-
tion progression, and lower serum low-
density lipoprotein and inflammatory 
markers and increases the treatment safety 
margin of active vitamin D sterols. 5 – 9 
More recently, sevelamer carbonate, a 
similar anion exchange resin in which 
chloride is replaced by carbonate, was 
approved by the FDA in 2007 and has 
been shown to be equally effective in 
lowering serum phosphorus with a 
reduced incidence of metabolic acido-
sis. 10 Lanthanum carbonate, approved by 
the FDA in 2004, is a non-calcium, 
metal-based phosphorus binder that has 
also been associated with lower serum 
calcium levels and a lower incidence of 
hypercalcemia. 11,12 However, studies in 
both animals and humans have suggested 
that long-term lanthanum administra-
tion carries the risk of blood and tissue 
accumulation. 13,14 
 Block  et al. 15 (this issue) present the 
results of a phase I clinical trial examining 
the safety and effi  cacy of SBR759, a novel 
non-calcium, metal-based phosphorus 
binder ( Figure 1 ). SBR759 is a polymeric 
complex of starch with ferric iron(III) as 
its phosphate-binding cation. In a single-
center open-label study of 44 adult hemo-
dialysis patients, SBR759 was shown to be 
well tolerated and eff ective, with all treat-
ment groups achieving clinically signifi -
cant reductions in serum phosphorus. 
Iron-containing phosphorus binders have 
been investigated in the past, with mixed 
results. One trial in 32 dialysis-dependent 
patients showed that a non-ionic ferric 
polymaltose complex (Ferrum, Haus-
mann Laboratories) decreased serum 
phosphorus but was not as eff ective as 
conventional phosphate binders. 16 An 
open-label crossover study of ferric citrate 
in 45 hemodialysis patients showed a 
reduction in serum phosphorus, but it was 
not as eff ective as calcium carbonate. 17 
Finally, a phase II study of iron-magne-
sium hydroxycarbonate (Fermagate, 
INEOS Healthcare) in hemodialysis 
patients demonstrated promising control 
of serum phosphorus. 18 However, the trial 
was complicated by a high number of 
adverse events and treatment discon-
tinuations in the higher-dosage arm. In 
addition, treatment was associated with 
a dose-dependent increase in serum 
magnesium. 
 SBR759 off ers a signifi cant advantage 
in that it is given as a powder formula-
tion. Currently only one other non-
 calcium-based phosphate binder, 
sevelamer carbonate, is available in pow-
der form. 10 Block  et al. 15 describe 
SBR759 powder as neutral, nearly taste-
less, and odorless, and patients were able 
to mix their assigned dose into 30 – 60 cc 
of water or room-temperature non-
 carbonated, non-acidic juice. This 
method of delivery will probably be pre-
ferred by the vast majority of CKD 
patients, who already have a high pill 
burden. Although future studies are 
required, SBR759 may play an important 
role in the improvement of compliance 
with binders and may potentially pro-
vide better control of serum phosphorus. 
Finally, the powder formulation would 
provide another option for pediatric and 
elderly patients unable to take pills. 
 One potential concern with SBR759 is 
its metal base, using iron as its phosphate-
binding cation. In particular, because 
there are no physiological mechanisms for 
iron excretion, iron accumulation can 
pose significant health risks, many of 
which have been documented in CKD 
patients. 19 However, as Block  et al. 15 note, 
iron therapy, both enteral and parenteral, 
is a very common component of CKD 
therapy and has an extensive safety profi le. 
Using information from Block  et al. 15 
regarding the low bioavailability of the 
 Figure 1  |   Could iron be the new super phosphate binder? 
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ferric iron in SBR759, we calculate that the 
maximum daily dose of SBR759 (22.5 g / d) 
would amount to roughly the same 
amount of bioavailable iron as a single fer-
rous sulfate tablet (325  mg). In addition, it 
is well recognized that enteral iron absorp-
tion in the setting of CKD is poor, probably 
because of elevated levels of hepcidin, a key 
regulator of iron homeostasis. While it 
is possible that, in the future, targeted 
therapy against hepcidin could dramati-
cally increase enteral iron absorption, cur-
rently it remains unlikely that SBR759 use 
would lead to iron overload. Regardless, 
given the previous experience with alumi-
num-based phosphate binders and lantha-
num, the potential toxicity associated with 
metal accumulation should be evaluated 
in future studies in order to assure that 
long-term use of SBR759 does not lead to 
iron accumulation. 
 Th e development of hypocalcemia was 
an unexpected and puzzling fi nding. Six 
of the 44 patients experienced hypocal-
cemia (serum calcium   <  8.4  mg / dl), with 
an increased frequency seen in the higher-
dosage cohorts; five of the six patients 
with hypocalcemia were receiving dosages 
of either 11.25 or 15 g / d. One serious 
adverse event was reportedly due to 
hypocalcemia, although it was not consid-
ered to be  “ treatment related. ” Given that 
this is a phase I trial with a small number 
of patients, it is difficult to ascertain 
whether hypocalcemia will remain a con-
cern in future trials. 
 Unfortunately, it is diffi  cult to explore 
the pathophysiology of the observed 
hypocalcemia given the lack of any serum 
calcium data despite the presentation of a 
myriad of other biochemical parameters, 
including intact parathyroid hormone and 
vitamin D levels. In addition, the specifi c 
biochemical profi les of the six hypocal-
cemic patients are not included. The 
authors do note that historical serum cal-
cium levels were not used as inclusion 
criteria, and 70 % of the patients with this 
adverse event had a previous history of 
hypocalcemia; one patient had undergone 
a parathyroidectomy 4 months before 
study entry. 
 Previous studies in both animals and 
humans have failed to demonstrate the 
development of hypocalcemia after 
treatment with iron-based phosphate 
binders. 16 – 18,20 In fact, in non-uremic 
rats treated with cross-linked iron dex-
tran, there was increased intestinal cal-
cium absorption with an occasional 
increase in serum ionized calcium. 20 
Parenteral iron administration has been 
associated with an elevation in fi broblast 
growth factor-23 (FGF-23) levels in 
individuals with normal renal function, 
which potentially over time may lead to 
decreased hydroxylation of 25(OH)D 
and hypocalcemia. 21 However, FGF-23 
levels are already markedly elevated in 
dialysis patients, and thus this potential 
interaction seems unlikely. 
 In summary, Block  et al. 15 have pro-
vided evidence that a novel phosphate 
binder, SBR759, is both eff ective and well 
tolerated in dosages up to 15 g / d. A notable 
advantage of SBR759 is its powder formu-
lation, which theoretically could improve 
patient compliance by reducing pill bur-
den and facilitate ingestion in pediatric 
and elderly patients. Whether this com-
pound could prevent or attenuate vascular 
calcifi cation will require further studies. 
Th e potential for iron accumulation and 
hypocalcemia seems minor, but both will 
need to be addressed before the wide-
spread adoption of this binder. Finally, as 
we continue our search for the optimal 
phosphate binder, we need to keep in 
mind that advances in the regulation of 
intestinal phosphorus absorption may 
lead to the development of a new class of 
agents that may potentially target the 
type IIb Na-Pi cotransporter directly. 
Furthermore, phosphorus control may 
even become a non-issue if prolonged 
daily or nocturnal dialysis becomes the 
rule rather than the exception. 
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